pertuzumab
E263659
Pertuzumab is a monoclonal antibody used in targeted therapy for HER2-positive breast cancer, often administered alongside trastuzumab and chemotherapy.
All labels observed (1)
| Label | Occurrences |
|---|---|
| pertuzumab canonical | 7 |
How this entity was disambiguated
This entity first appeared as the object of triple T2370981 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: pertuzumab Context triple: [Herceptin, isIndicatedInCombinationWith, pertuzumab]
-
A.
Herceptin
Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
-
B.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
C.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
D.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
-
E.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: pertuzumab Target entity description: Pertuzumab is a monoclonal antibody used in targeted therapy for HER2-positive breast cancer, often administered alongside trastuzumab and chemotherapy.
-
A.
Herceptin
Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
-
B.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
-
C.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
D.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
-
E.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
HER2-targeted therapy
ⓘ
antineoplastic agent ⓘ biologic drug ⓘ monoclonal antibody ⓘ therapeutic antibody ⓘ |
| administeredAs | intravenous infusion ⓘ |
| approvedBy |
Food and Drug Administration
ⓘ
surface form:
U.S. Food and Drug Administration
|
| ATCCode | L01FD02 ⓘ |
| belongsToPathway | HER2/ERBB signaling pathway ⓘ |
| bindsTo | HER2 dimerization domain ⓘ |
| blackBoxWarning |
embryo-fetal toxicity
ⓘ
left ventricular dysfunction ⓘ |
| canCause |
cardiac dysfunction
ⓘ
infusion-related reactions ⓘ |
| commonAdverseEffect |
alopecia
ⓘ
diarrhea ⓘ fatigue ⓘ nausea ⓘ neutropenia ⓘ rash ⓘ |
| contraindicatedIn | pregnancy ⓘ |
| developedBy |
Genentech
ⓘ
Roche ⓘ |
| drugClass |
anti-HER2 agent
ⓘ
humanized monoclonal antibody ⓘ |
| FDAApprovalYear | 2012 ⓘ |
| firstLineTherapyFor | HER2-positive metastatic breast cancer in combination with trastuzumab and docetaxel ⓘ |
| hasTradeName | Perjeta ⓘ |
| indicationRegion |
European Union
ⓘ
United States of America ⓘ
surface form:
United States
|
| isCombinationBackboneWith | trastuzumab and docetaxel ⓘ |
| isRecombinant | true ⓘ |
| mechanismOfAction |
blocks ligand-dependent HER2 signaling
ⓘ
inhibits HER2 dimerization ⓘ mediates antibody-dependent cell-mediated cytotoxicity ⓘ |
| molecularType | IgG1 kappa monoclonal antibody ⓘ |
| oftenUsedWith |
chemotherapy
ⓘ
docetaxel ⓘ paclitaxel ⓘ Herceptin ⓘ
surface form:
trastuzumab
|
| routeOfAdministration | intravenous ⓘ |
| targets |
ERBB2
ⓘ
HER2 receptor ⓘ |
| usedFor |
HER2-positive breast cancer
ⓘ
adjuvant treatment of HER2-positive breast cancer ⓘ early-stage HER2-positive breast cancer ⓘ metastatic HER2-positive breast cancer ⓘ neoadjuvant treatment of HER2-positive breast cancer ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: pertuzumab Description of subject: Pertuzumab is a monoclonal antibody used in targeted therapy for HER2-positive breast cancer, often administered alongside trastuzumab and chemotherapy.
Referenced by (7)
Full triples — surface form annotated when it differs from this entity's canonical label.